Document is current
Any future updates will be listed below
-
Authors
Tokunaga, Kenichiro https://orcid.org/0000-0002-1154-392X
Matsui, Kunihiko
Oshikawa, Hideto
Matsui, Toshihiro
Tohma, Shigeto
- License Information
-
More Information
Article History
Received: 30 September 2020
Revised: 16 October 2020
Accepted: 21 October 2020
First Online: 29 October 2020
Compliance with ethical standards
:
: Kenichiro Tokunaga: none; Kunihiko Matsui: none; Hideto Oshikawa: none; Toshihiro Matsui was supported by research grants from Chugai Pharmaceutical Co., Ltd., and Janssen Pharmaceutical K.K.; Shigeto Tohma: consulting or advisory role for Pfizer Japan Inc.; speakers’ bureau from Pfizer Japan Inc., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Astellas Pharma Inc., AYUMI Pharmaceutical Co., and Chugai Pharmaceutical Co., Ltd.
: The NinJa dataset, and all subsequent studies utilizing pre-existing registry data, was approved by the Sagamihara National Hospital institutional review board. No additional ethical approvals were required by the central institutional review board for this specific study.
: Individual written consent was waived under the current Japanese ethical guidelines for epidemiological studies because of the purely observational nature of the NinJa dataset.
: Individual written consent was waived under the current Japanese ethical guidelines for epidemiological studies because of the purely observational nature of the NinJa dataset.
: Not applicable
